Related Experiment Video

Updated: Nov 15, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.5K

Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary

Miaomiao Sang1, Yu Fu2, Chenmin Wei1

  • 1Department of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|March 8, 2021
PubMed

Insights

Primary aldosteronism (PA) and essential hypertension (EH) show comparable microvascular endothelial function and biomarkers. This study found no significant differences in endothelial dysfunction markers between PA and EH patients.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Hypertension Research

Background:

  • Primary aldosteronism (PA) is associated with a higher cardiovascular event risk compared to essential hypertension (EH).
  • Endothelial dysfunction is a key predictor of cardiovascular events, but its comparative role in PA versus EH remains unclear.

Purpose of the Study:

  • To investigate differences in endothelial dysfunction biomarkers, including Asymmetric dimethylarginine (ADMA), E-selectin, and Plasminogen activator inhibitor-1 (PAI-1), between PA and EH patients.
  • To assess and compare microvascular endothelial function in patients with PA and EH.

Main Methods:

  • Biomarkers of endothelial dysfunction were quantified using enzyme-linked immunosorbent assay (ELISA).
  • Microvascular endothelial function was evaluated using Pulse Amplitude Tonometry (PAT).

Main Results:

  • While ADMA levels showed a statistical difference among aldosterone-producing adenoma (APA), idiopathic hyperaldosteronism (IHA), and EH groups (p=0.04), post-hoc analysis revealed no significant differences between APA and EH or IHA.
  • Levels of PAI-1 and E-selectin, along with microvascular endothelial function, did not differ significantly between PA and EH groups.

Conclusions:

  • This study found no significant differences in endothelial dysfunction biomarkers or microvascular endothelial function between patients with PA and EH.
  • The microvascular endothelial function in patients with PA and EH is comparable.
Abstract

Keywords:
E-selectinPrimary aldosteronismasymmetric dimethylarginineperipheral arterial tonometryplasminogen activator inhibitor-1

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 200007:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

44.1K
Non-invasive Assessment of Microvascular and Endothelial Function05:41

Non-invasive Assessment of Microvascular and Endothelial Function

Published on: January 29, 2013

16.4K

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
186
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.4K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
326
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1000
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
317
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
663